Trial Profile
A Randomized, Double Blind, Active Comparator, Parallel-group Study to Determine Whether the Combination of Valsartan and Aliskiren Provides Cardioprotection in African American Patients With Hypertension and Elements of the Metabolic Syndrome
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Aliskiren/valsartan (Primary) ; Ramipril
- Indications Hypertension; Metabolic syndrome
- Focus Therapeutic Use
- Acronyms SAAVE
- 23 Aug 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 15 Sep 2011 New trial record